Galapagos
Scipher Medicine, Galapagos Sign IBD Drug Development Deal
The companies will jointly validate novel drug targets identified by Scipher's molecular interaction network platform for patients with inflammatory bowel disease.
Charles River Laboratories Buying BioFocus, Argenta from Galapagos for up to $187M
NEW YORK (GenomeWeb News) – Charles River Laboratories has signed a definitive agreement to purchase Galapagos' BioFocus and Argenta service division operations for a total consideration of €134 million ($187 million), the companies announced today.
Galapagos' BioFocus Business Extends Contract with Amgen
The extension calls for the use of BioFocus' target discovery platform to deliver novel targets in support of Amgen's therapeutic programs.
BioFocus Joins Argenta, Genentech Research Alliance
BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology, and ADME services.
Jul 12, 2010
NIH Extends Agreement with Galapagos for MLSMR
Jun 28, 2010
Galapagos Raises $430K through Warrants Exercise
Jan 20, 2010
EMBL Launches Genomic-Based Drug Data Resource
Oct 16, 2009
Galapagos Raises $27.1M in Share Placement
Oct 14, 2009
Galapagos Expands Merck Drug Target Pact
Jul 22, 2009
Mar 6, 2009
News Scan : Mar 6, 2009
Premium
Mar 6, 2009